Written and peer-reviewed by physicians—but use at your own risk. Read our disclaimer.

banner image

amboss

Trusted medical answers—in seconds.

Get access to 1,000+ medical articles with instant search
and clinical tools.

Try free for 5 days

Oral anticoagulants

Last updated: January 6, 2021

Summarytoggle arrow icon

Anticoagulants are used for treating and preventing embolic events. The most common oral anticoagulatory agents are vitamin K antagonists such as warfarin and phenprocoumon. Non-vitamin K antagonist oral anticoagulants (NOACs) like dabigatran and rivaroxaban have also gained popularity in recent years. Vitamin K antagonists inhibit the enzyme vitamin K epoxide reductase, thereby blocking hepatic synthesis of the active, reduced form of vitamin K (needed for carboxylation of coagulation factors II, VII, IX, and X, protein C, protein S). This effect can last for several days, which complicates exact dosing and makes regular monitoring necessary. Vitamin K antagonists are also metabolized by C-P450 (CYP) enzymes and therefore interact with a broad range of foods and drugs. NOACs act selectively via inhibition of thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, edoxaban). Because of their comparatively short half-life and fewer interactions, NOACs are easier to control and administer than warfarin and do not require regular monitoring to ensure their efficacy and safety. For all substances, it is important to consider the dose-dependent risk of bleeding, especially when combining different substances that affect hemostasis (e.g., aspirin, clopidogrel, ticagrelor).

Overview of commonly used oral anticoagulants

Substances Mechanism of action
Advantages Disadvantages
Vitamin K antagonists (coumarins)

Phenprocoumon

Warfarin [1][2]

Direct oral anticoagulants
Direct oral thrombin inhibitors

Dabigatran [3]

  • Easily manageable (similar to heparins) when administered orally
    • Regular monitoring of coagulation parameters is not required → improved patient compliance
  • Antidotes available in the case of life-threatening bleeding
  • Costly
  • Limited clinical experience with these drugs
  • Not recommended, and partially contraindicated, in patients with artificial cardiac valves
  • Not suited for patients with valvular atrial fibrillation
Direct oral factor Xa inhibitors

Apixaban

Rivaroxaban

Edoxaban

  • Selective and direct inhibition of factor Xa
General notes regarding oral anticoagulation
Indications for all oral anticoagulants

Expected laboratory changes

The most important side effect of all oral anticoagulants is a dose-dependent increase in bleeding risk.

You can memorize the most important oral anticoagulants with DRAW: Dabigatran, Rivaroxaban, Apixaban, and Warfarin.

RivaroXaban, apiXaban, and edoXaban are factor Xa inhibitors.

WARsaw is an EXTRaordinary Place To check out: WARfarin affects the EXTRinsic pathway; therefore, PT should be regularly checked.

Comparison of heparin and warfarin

Anticoagulant Route of administratIon Mechanism of action Monitoring Reversal agents
Heparin
  • Intravenous
  • Subcutaneous
  • Activates antithrombin↓ action of factors IIa and Xa
  • Site of action: blood
  • Rapid onset of action
  • Shorter half time: duration of action is several hours
  • PTT (affects intrinsic pathway)
Warfarin
  • Oral
  • PT or INR (affects extrinsic pathway)

Coumarins

Individuals with protein C deficiency are at a higher risk of developing warfarin necrosis.

Direct factor Xa inhibitors and direct thrombin inhibitors

RivaroXaban and apiXaban can be reversed with andeXanet alfa.

References:[5][6][7][8][9][10][11]

We list the most important adverse effects. The selection is not exhaustive.

Drugs Indications
Coumarins

Phenprocoumon

Warfarin

Direct thrombin inhibitors

Dabigatran

Direct factor Xa inhibitors

Apixaban

Rivaroxaban

Edoxaban

References:[12][13][14][15][16]

Warfarin crosses the placenta and is teratogenic, in contrast to heparin, which does not cross the placenta.

References:[17][18][19]

We list the most important contraindications. The selection is not exhaustive.

Warfarin interactions

Warfarin is metabolized by cytochrome P450 (CYP) enzymes. Its effects can be significantly impacted by a variety of interactions; for this reason, warfarin serum levels should be monitored regularly.

P450 inducers: warfarin levels (Chronic Alcoholics Steal Phen-Phen and Never Refuse Greasy Carbs): C - Chronic alcohol use, S - St. John's wort, P - Phenytoin, P - Phenobarbital, N - Nevirapine, R - Rifampin, G - Griseofulvin, C - Carbamazepine

P450 inhibitors can be remembered with “sickfaces.com group”: S - Sulfonamides, I - Isoniazid, C - Cimetidine, K - Ketoconazole, F - Fluconazole, A - Alcohol (binge drinking), C - Ciprofloxacin, E - Erythromycin, S - Sodium valproate, C - Chloramphenicol, O - Omeprazole, M - Metronidazole, G - Grapefruit juice
References:[20][21][22]

  • Bridging anticoagulation: the administration of heparin for the duration of the transient hypercoagulable state caused by warfarin therapy. Heparin prevents coagulation by activating antithrombin.
  • Preoperative bridging therapy
    1. Stop coumarin administration 5–6 days before surgery.
    2. Administer a therapeutic dose of the bridging drug 3 days before surgery; , with the last dose administered 24 hours before the procedure.
    3. Resume the bridging drug and warfarin after surgery; ; administer the bridging drug for 4–6 days post-surgery.

References:[23]

  1. Tran HA, Chunilal SD, Harper PL, et al. An update of consensus guidelines for warfarin reversal. Med J Aust. 2013; 198 (4): p.198-199. doi: 10.5694/mja12.10614 . | Open in Read by QxMD
  2. Warfarin reversal Guideline.
  3. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369 (13): p.1206-1214. doi: 10.1056/NEJMoa1300615 . | Open in Read by QxMD
  4. Antidote to Dabigatran Is Approved. http://www.jwatch.org/na39428/2015/10/22/antidote-dabigatran-approved. Updated: February 21, 2017. Accessed: February 21, 2017.
  5. Olson KR, Tarabar A. Warfarin and Superwarfarin Toxicity. Warfarin and Superwarfarin Toxicity. New York, NY: WebMD. http://emedicine.medscape.com/article/821038. Updated: December 12, 2016. Accessed: February 21, 2017.
  6. Saltzman JR. Approach to acute upper gastrointestinal bleeding in adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/approach-to-acute-upper-gastrointestinal-bleeding-in-adults.Last updated: November 12, 2015. Accessed: February 21, 2017.
  7. Warfarin Reversal. http://lifeinthefastlane.com/ccc/warfarin-reversal/. Updated: February 21, 2017. Accessed: February 21, 2017.
  8. Warfarin-induced skin necrosis. https://www.dermnetnz.org/topics/warfarin-induced-skin-necrosis. Updated: February 1, 2016. Accessed: February 21, 2017.
  9. Garcia DA, Crowther M. Management of bleeding in patients receiving direct oral anticoagulants. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/management-of-bleeding-in-patients-receiving-direct-oral-anticoagulants.Last updated: December 19, 2016. Accessed: February 21, 2017.
  10. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016; 41 (1): p.206-232. doi: 10.1007/s11239-015-1310-7 . | Open in Read by QxMD
  11. Kakagia DD, Papanas N, Karadimas E, Polychronidis A. Warfarin-induced skin necrosis. Ann Dermatol. 2014; 26 (1): p.96. doi: 10.5021/ad.2014.26.1.96 . | Open in Read by QxMD
  12. Ouellette DR. Pulmonary Embolism. Pulmonary Embolism. New York, NY: WebMD. http://emedicine.medscape.com/article/300901. Updated: June 22, 2016. Accessed: February 14, 2017.
  13. Christensen B. International Normalized Ratio (INR) Targets: Valvular Disease . International Normalized Ratio (INR) Targets: Valvular Disease . New York, NY: WebMD. http://emedicine.medscape.com/article/2172274-overview. Updated: December 10, 2014. Accessed: February 21, 2017.
  14. Aurigemma GP, Konkle BA, Gaasch WH. Antithrombotic therapy for prosthetic heart valves: Indications. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/antithrombotic-therapy-for-prosthetic-heart-valves-indications.Last updated: May 23, 2016. Accessed: February 21, 2017.
  15. Falck-ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (Suppl 2): p.e278S-325S. doi: 10.1378/chest.11-2404 . | Open in Read by QxMD
  16. Pai M, Douketis JD. Prevention of venous thromboembolic disease in surgical patients. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/prevention-of-venous-thromboembolic-disease-in-surgical-patients.Last updated: January 18, 2017. Accessed: February 21, 2017.
  17. Medscape. warfarin (Rx). warfarin (Rx). New York, NY: WebMD. http://reference.medscape.com/drug/coumadin-jantoven-warfarin-342182. Updated: February 21, 2017. Accessed: February 21, 2017.
  18. Weitz JI. Expanding use of new oral anticoagulants. F1000Prime Rep. 2014; 6 : p.93. doi: 10.12703/P6-93 . | Open in Read by QxMD
  19. Ginsberg JS, Crowther MA. Direct oral anticoagulants (DOACs) and pregnancy: A plea for better information. Thromb Haemost. 2016; 116 (4): p.590-591. doi: 10.1160/TH16-08-0602 . | Open in Read by QxMD
  20. Le T, Bhushan V. First Aid for the USMLE Step 1 2015. McGraw-Hill Education ; 2014
  21. Anticoagulants. http://www.medbullets.com/step1-heme/11030/anticoagulants. Updated: January 20, 2017. Accessed: February 21, 2017.
  22. Juurlink DN. Drug interactions with warfarin: what clinicians need to know. Can Med Assoc J. 2007; 177 (4): p.369-371. doi: 10.1503/cmaj.070946 . | Open in Read by QxMD
  23. Investigators TBS. Bridging anticoagulation: is it needed when warfarin is interrupted around the time of a surgery or procedure?. Circulation. 2012; 125 (12): p.e496-e498. doi: 10.1161/CIRCULATIONAHA.111.084517 . | Open in Read by QxMD